Corrigendum: Therapeutic effects of zoledronic acid-loaded hyaluronic acid/polyethylene glycol/nano-hydroxyapatite nanoparticles on osteosarcoma

Corrigendum: Therapeutic effects of zoledronic acid-loaded hyaluronic acid/polyethylene glycol/nano-hydroxyapatite nanoparticles on osteosarcoma

Saved in:

Bibliographic Details
Main Authors:	Yan Xu, Jingqi Qi, Wei Sun, Wu Zhong, Hongwei Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Bioengineering and Biotechnology
Subjects:	nanoparticle osteosarcoma zoledronic acid tumor therapy targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fbioe.2025.1601751/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Therapeutic Effects of Zoledronic Acid-Loaded Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticles on Osteosarcoma
by: Yan Xu, et al.
Published: (2022-05-01)

Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis
by: P Madhuchandra, et al.
Published: (2024-01-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

Zoledronate-induced orbital and ocular inflammation
by: Julia Dyrda, et al.
Published: (2025-03-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
by: N. V. Toroptsova, et al.
Published: (2021-10-01)

Case Report: Acute Unilateral Uveitis Induced by Infusion of Zoledronic Acid
by: Kadir Songür, et al.
Published: (2022-08-01)

Efficacy of zoledronic acid in treatment of hemodialysis patients with secondary hyperparathyroidism and osteoporosis
by: GUAN Bao-zhang, et al.
Published: (2016-01-01)

Successful rapid desensitization to zoledronic acid in a multiple myeloma patient
by: Federico Spataro, et al.
Published: (2025-03-01)

Dynamic changes in γδT cells and bone resorption markers after zoledronic acid in multiple myeloma: A prospective study
by: Chao-Hung Wei, et al.
Published: (2025-07-01)

Effects of a single intravaneous dose of zoledronic acid on bone healing following tooth extraction in ovariectomized rabbits
by: Esra Mavi, et al.
Published: (2021-11-01)

Risk of Osteonecrosis of the Jaw in Patients Treated with Zoledronic or Alendronic Acid: A Systematic Review
by: Aine Jakonyte, et al.
Published: (2025-06-01)

Fucoidan-decorated metal-zoledronic acid nanocomplexes suppress tumor metastasis by inducing ferroptotic cell death and enhancing cancer immunotherapy
by: Hsin-Ting Tsai, et al.
Published: (2025-06-01)

Treatment of osteoporosis in clinical practice: first experience with the Russian generic drug of zoledronic acid
by: N. V. Toroptsova, et al.
Published: (2022-05-01)

Risk Factors for Acute Febrile Reaction after Zoledronic Acid Treatment for Primary Osteoporosis
by: WU Hongliang, et al.
Published: (2022-06-01)

Gambogic acid suppresses osteosarcoma progression through upregulation of FOXO3a
by: Yawei Hu, et al.
Published: (2025-06-01)

Comparative Evaluation of Two Different Single-Session Radiotherapy Regimens along with Zoledronic Acid in Painful Bone Metastases
by: Sanwaria Meenakshi, et al.
Published: (2024-09-01)

Comparison of the effects of zoledronic acid versus denosumab on bone metabolism, inflammatory response, and immunoglobulins in breast cancer patients with bone metastases
by: Zhang Xian, et al.
Published: (2025-01-01)

Supra-Physiological Levels of Magnesium Counteract the Inhibitory Effect of Zoledronate on RANKL-Dependent Osteoclastogenesis
by: Lorenzo Caselli, et al.
Published: (2025-05-01)

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01)

Development of nano hydroxyapatite loaded gellan gum nanocomposite scaffold for the regeneration of bone tissue affected by osteosarcoma
by: Huaidong Wang, et al.
Published: (2025-05-01)

Recurrent metastatic high-grade osteosarcoma: Disease stabilization and successful pregnancy outcome following aggressive multimodality treatment
by: Monica Khurana, et al.
Published: (2018-01-01)

Systemic strategies for osteosarcoma: advances and future directions
by: Vivek Kumar Morya, et al.
Published: (2025-07-01)

Hybrid surface layers with antibacterial and anti-inflammatory activity for implants materials
by: Mariia A. Piatkova, et al.
Published: (2025-05-01)

Green analytical chemistry and quality by design: A combined approach towards simultaneous determination of Letrozole with its co-administered Zoledronic Acid for cancer patients
by: Nourhan A. Abd El-Fatah, et al.
Published: (2024-12-01)

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
by: İrem Öner, et al.
Published: (2025-02-01)

Results of 2-year open multicenter observational study for efficacy, safety, tolerability and quality of life impact of zoledronic acid in women with postmenopausal osteoporosis in real-world settings in Russian Federation
by: O. M. Lesnyak, et al.
Published: (2021-06-01)

Zoledronate interrupts pre-osteoclast-induced angiogenesis via SDF-1/CXCR4 pathway
by: Mohamed Awad, et al.
Published: (2024-12-01)

Osteosarcoma: current insights and advances
by: Guraustin S. Brar, et al.
Published: (2025-06-01)

Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies
by: Mahmoud Zhra, et al.
Published: (2025-04-01)

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma
by: Cong Luo, et al.
Published: (2025-01-01)

Commentary: Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Nan Zhang, et al.
Published: (2025-07-01)

Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np)
by: Kong Lingyan, et al.
Published: (2025-01-01)

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
by: Kazuhiro Nagao, et al.
Published: (2016-01-01)

The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing
by: Zuoyao Long, et al.
Published: (2024-12-01)

A catalase-powered self-oxygen-generating soft nanomotor for photodynamic therapy of osteosarcoma
by: Xinyi Tan, et al.
Published: (2025-06-01)

Multidisciplinary approach to the accurate diagnosis of parosteal osteosarcoma
by: Miroslav Kilian, et al.
Published: (2025-07-01)

SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data
by: Han-jing Zhang, et al.
Published: (2025-08-01)

The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma
by: Qilong Su, et al.
Published: (2025-06-01)

Injectable hyaluronate-L- cysteine gel potentiates photothermal therapy in osteosarcoma via vorinostat-copper cell death
by: Sizhen Wang, et al.
Published: (2024-12-01)

Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma
by: Yi Ding, et al.
Published: (2025-02-01)